Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21
Journal of Medicinal Chemistry · 09.03.2023 · 66 (5) · 3431-3447
DOI: 10.1021/acs.jmedchem.2c01933 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 20.02.2023. Verfasst von Fabian Göricke und 20 weiteren Autor:innen. Beteiligte Einrichtung: Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany. Hauptthemen laut MEDLINE: Ubiquitin-Specific Proteases, Signal Transduction. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer, Merck KGaA, Genentech.
Abstract (Originalsprache)
USP21 belongs to the ubiquitin-specific protease (USP) subfamily of deubiquitinating enzymes (DUBs). Due to its relevance in tumor development and growth, USP21 has been reported as a promising novel therapeutic target for cancer treatment. Herein, we present the discovery of the first highly potent and selective USP21 inhibitor. Following high-throughput screening and subsequent structure-based optimization, we identified BAY-805 to be a non-covalent inhibitor with low nanomolar affinity for USP21 and high selectivity over other DUB targets as well as kinases, proteases, and other common off-targets. Furthermore, surface plasmon resonance (SPR) and cellular thermal shift assays (CETSA) demonstrated high-affinity target engagement of BAY-805, resulting in strong NF-κB activation in a cell-based reporter assay. To the best of our knowledge, BAY-805 is the first potent and selective USP21 inhibitor and represents a valuable high-quality in vitro chemical probe to further explore the complex biology of USP21.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research & Development, Pharmaceuticals, Bayer AG, 42096 Wuppertal, Germany.
- Structural Genomics Consortium, University of Toronto, Toronto, Ontario M5G 1L7, Canada.
- Nuvisan Innovation Campus Berlin, 13353 Berlin, Germany.
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany.
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
ORCID-Profile: Hartmut Beck, Peter J Brown, Vijayaratnam Santhakumar, Masoud Vedadi, Cheryl H Arrowsmith
Förderung
- Bayer
- Merck KGaA
- Genentech
- Kungliga Tekniska H?gskolan
- Diamond Light Source
- Pfizer
- Bristol-Myers Squibb
- Genome Canada
Zitieren
APA
Göricke, F., Vu, V., Smith, L., Scheib, U., Böhm, R., Akkilic, N., Wohlfahrt, G., Weiske, J., Bömer, U., Brzezinka, K., Lindner, N., Lienau, P., Gradl, S., Beck, H., Brown, P. J., Santhakumar, V., Vedadi, M., Barsyte-Lovejoy, D., Arrowsmith, C. H., …, & Petersen, K. (2023). Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21. Journal of Medicinal Chemistry, 66(5), 3431-3447. https://doi.org/10.1021/acs.jmedchem.2c01933
Vancouver
Göricke F, Vu V, Smith L, Scheib U, Böhm R, Akkilic N, et al. Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21. Journal of Medicinal Chemistry. 2023;66(5):3431-3447. doi:10.1021/acs.jmedchem.2c01933
BibTeX
@article{Gricke2023,
author = {Göricke, Fabian and Vu, Victoria and Smith, Leanna and Scheib, Ulrike and Böhm, Raphael and Akkilic, Namik and Wohlfahrt, Gerd and Weiske, Jörg and Bömer, Ulf and Brzezinka, Krzysztof and Lindner, Niels and Lienau, Philip and Gradl, Stefan and Beck, Hartmut and Brown, Peter J and Santhakumar, Vijayaratnam and Vedadi, Masoud and Barsyte-Lovejoy, Dalia and Arrowsmith, Cheryl H and Schmees, Norbert and Petersen, Kirstin},
title = {Discovery and Characterization of BAY-805, a Potent and Selective Inhibitor of Ubiquitin-Specific Protease USP21},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {5},
pages = {3431--3447},
doi = {10.1021/acs.jmedchem.2c01933}
}
EUVIMED